85.7 F
Los Angeles
Tuesday, September 8, 2026
Home Market Novartis’s fa...

Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

© 2026, . Disclaimer: The part of contents and images are collected and revised from Internet. Contact us ( info@uscommercenews.com) immidiatly if anything is copyright infringed. We will remove accordingly. Thanks!